Mary K. Caffrey
Advances in treating multiple myeloma have transformed the field over the past decade, giving clinicians more effective therapy options for newly diagnosed patients who are candidates for stem cell transplant and those who are not.
But the best may be yet to come, with 2 promising monoclonal antibodies on the horizon, according to Kenneth C. Anderson, MD, of the Dana-Farber Cancer Institute. Anderson discussed treatment advances on March 15, 2014, at the National Comprehensive Cancer Network’s (NCCN’s) 19th Annual Conference: Advancing the Standard of Cancer Care, held in Hollywood, Florida.
Anderson said the 9 new approvals for multiple myeloma from the FDA have prolonged median survival for patients 2 to 3 years, with most patients now living 5 to 7 years with the disease. “In spite of all this, we still need novel agents,” he said, before sharing his optimism about therapies in the pipeline.
The addition of bortezomib has rewritten NCCN guidelines in recent years, and the 2014 version Anderson shared features the proteasome inhibitor in various combinations with immunomodulatory drugs in 5 of the 6 preferred regimens for patients who are transplant candidates.
Positive results on bortezomib-based regimens continue to come in; Anderson reviewed data presented at the American Society of Hematology (ASH) meeting in New Orleans in December 2013, which he said show that the treatment consistently improves progression-free survival by an average of 9 months, as well as overall survival, with a median of 84 months reached.1
For patients ineligible for transplant, a new standard of care has emerged, Anderson said. Based on the results of the FIRST trial presented at ASH in December, lenalidomide and low-dose dexamethasone (len-dex) has been moved into the NCCN guidelines. At a massive, standing-room–only plenary session, Thierry Facon, MD, presented results showing a 28% better survival rate for patients in the trial than for patients taking the previous standard of melphalan, prednisone, and thalidomide (MPT).2
Anderson emphasized the real-world practicality that Facon noted at ASH1: the FIRST trial (Frontline Investigation Of Lenalidomide + Dexamethasone Versus Standard Thalidomide) involved a large group of relatively older patients, much closer to the group that will be developing multiple myeloma as the population ages.
But for all the good news, said Anderson, multiple myeloma remains incurable. New approaches, he suggested, are needed to treat and ultimately prevent relapse. “I want to get you excited about the future,” Anderson said. “We think we’re finally going to get a monoclonal antibody or two.”
The bright spots are elotuzumab, which is currently in phase III trials but has shown very promising results in combination with len-dex, and daratumumab, which in June 2013 became the first
single-agent monoclonal antibody to receive FDA breakthrough status for relapsed and refractory multiple myeloma.3
Anderson’s final point may be the most exciting of all: It’s not just the newly diagnosed patients who are benefitting from the advances, but patients who have relapsed as well. Incorporation of novel therapies at all stages of disease is further improving patient outcomes, he said. EBO
At the 19th Annual Conference of the National Comprehensive Cancer Network (NCCN), held March 12-15, 2014, experts reviewed research and presented updates to the NCCN Clinical Practice Guidelines in Oncology. The conference also featured a roundtable discussion on how the early months of implementing the Affordable Care Act are affecting the delivery of cancer care. Beyond treatment for cancer, NCCN issued updates to last year’s survivorship guidelines as well as new recommendations in the realm of cancer screening.
For complete NCCN guidelines, create a profile and visit: http://www.nccn.org/professionals/default.aspx.
For the August 2013 NCCN Bone Health Task Force Report, visit: http://www.nccn.org/JNCCN/supplements/PDF/bone_health_cancer_care_tf.pdf.